Navigation Links
Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
Date:7/14/2009

HORSHOLM, Denmark, July 14 /PRNewswire/ -- The Board of Directors of Santaris Pharma has approved the Interim Report for the period 1 January to 30 June 2009.

    - The loss after tax realised in the 2nd quarter of 2009 was
      21,6m DKK (2,9m EUR) compared to 29,8m DKK (4,0m EUR) in the 2nd
      quarter of 2008.

    - As at June 30, 2009 the capital resources totalled 175,4m
      DKK (23,6m EUR).

    - In Q2 the SPC3649 compound targeting hepatitis C finalized a
      single dose First/In/Man study with encouraging results and a multiple
      ascending dose study in healthy volunteers is scheduled to commence in
      Q3 2009.

    - Santaris Pharma's new lead candidate SPC4955 targeting
      apoliproteinB, the major cholesterol carrying protein in the blood, has
      been selected for preclinical trials.

    - Lead candidates targeting PCSK9, which is known to play a
      critical role in regulating cholesterol levels, have been selected for
      pharmacological studies.

    - The Collaboration with the Company's 3rd partner, Wyeth, was
      initiated during the first months of 2009 and is progressing according
      to the plan.


    (Logo:http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

During the first half of 2009 Santaris Pharma continued to make satisfactory progress in its research and development programs within miRNA, metabolic disorders and infectious diseases. Key milestones achieved and other events during the quarter are summarized below.

Development

SPC3649-HCV

SPC3649 is a potent and specific inhibitor of microRNA-122 known to be involved in cholesterol metabolism and in hepatitis virus replication in the liver. In April 2009, Santaris Pharma completed a Phase I First-in-Man single dose study of SPC3649 with 60 healthy volunteers and t
'/>"/>

SOURCE Santaris Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Research and Markets ( http://www.researchandmarkets.com/research/nqxxt3/biomarkers ... new report "Biomarkers - Technologies, Markets and ... This report follows the broad definition of a ... measured and evaluated as an indicator of normal ... responses to a therapeutic intervention. Tests based on ...
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 ... leader in Personalized Medicine, is excited to announce ... Genetic Testing to Optimize the Management of Pain”. ... available at Medscape.com for the next year. The ... professionals how to recognize inadequate pain treatments, integrate ...
(Date:3/4/2015)... Follow us on LinkedIn - ... growing technologies in the life sciences industry. Growing global ... growth in nucleic acid detection technologies like qPCR and ... will continue to benefit the qPCR and dPCR instruments ... pharma, biotech, food & beverage to animal feed, will ...
(Date:3/3/2015)... and TORONTO, March 3, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... quarter and seventh-month period ended December 31, 2014. ... fiscal year end from May 31 to December 31. ... are reporting today are for the quarter and the ...
Breaking Biology Technology:Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 2Global Biomarkers Report 2014-2024 - Technologies, Markets and Companies 3Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... SHANGHAI, July 15 /PRNewswire-Asia-FirstCall/ -- ... a leading Chinese firm,specializing in the manufacture, research, development, ... results for,the fourth quarter and fiscal year ended March ... 2009 Highlights, -- Net sales increased ...
... Mass., July 14 The Huffington Post -- ,The ... with astronomer Bob Berman) " Biocentrism." The article by ... universe. The Huffington Post is ranked the most powerful ... over 20 million thought-leaders, and has featured celebrity contributors from politics ...
... EnVivo Pharmaceuticals today announced at the Alzheimer,s Association 2009 ... deficits observed in an Alzheimer,s disease transgenic animal model after ... data was disclosed as part of the preclinical characterization of ... , EVP-0962 is a proprietary small molecule that ...
Cached Biology Technology:China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13New Scientific Worldview 'Biocentrism' Featured in The Huffington Post - #1 Weblog in the World 2EnVivo Pharmaceuticals Announces Reversal of Cognitive Deficits in Alzheimer's Disease Transgenic Mouse Model With Gamma-Secretase Modulator 2
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
(Date:2/5/2015)... Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... ( http://www.nxt-id.com/ ) as part of its 2015 marketing ... Company launched its new consumer website for Wocketwallet.com earlier ... CEO of NXT-ID said, "Our new corporate website naturally ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... researchers are developing two inexpensive technologies that may be ... recent outbreak of E. coli in contaminated spinach. , ... , The first method uses a laser to ... about three times faster and one-tenth as expensive as ...
... how much detail one remembers of an event depends on ... "package" the memory. , The research may help to explain ... as a car accident, and yet vividly recall all of ... using functional magnetic resonance imaging (fMRI), the scientists were able ...
... (UC) environmental health researchers have determined that firefighters are ... cancer than workers in other fields. , Their findings ... the past didn't do a good job in protecting ... the researchers say. , The researchers found, for ...
Cached Biology News:Researchers develop technologies to devour food pathogens 2Researchers develop technologies to devour food pathogens 3Memories: It's all in the packaging, scientists say 2Firefighters face increased risk for certain cancers 2
... For nucleofection of optimized cell lines ... protocol including the nucleofection parameters. Nucleofector ... with the Nucleofector Device., Different cell ... kit. The corresponding efficiencies and viabilities ...
... used with its manganese-containing reaction buffer, converts ... of short (1825 bp) interfering RNAs (siRNA) ... 1.3 units (1 l) of ShortCut RNase ... of dsRNA into siRNA suitable for RNA ...
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
... are cytopathic effect inhibition assays, also known as ... tissue culture supernatents; serum from PK studies and ... is defined as the quantity of interferon required ... viral infection by 50%. All standards ...
Biology Products: